Pfizer said on Wednesday it has entered an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines, obtaining exclusive rights outside Greater China to develop, manufacture and commercialize three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs focused on autoimmune diseases. Starna will receive an upfront payment of $330 million and is eligible for up to $2.3 billion in development and commercial milestone payments, plus royalties on net sales of approved products.
Pfizer also receives rights to use Starna’s proprietary in vivo CAR-T technology in inflammation and immunology and in oncology, options to license compounds from a separate research collaboration, and an option to expand its territory to include Greater China. Pfizer will lead clinical development outside Greater China, plans to manufacture the finished drug product for the initial clinical trials at its facilities in the United States, and will have sole control over commercialization outside Greater China for all products.